| Role |
Name |
Disclosure |
Details |
| Author | Chakri Yarlagadda, MD, FACC, Consulting Staff, Section of Cardiology, St Elizabeth Hospital | Nothing to disclose | Details | | Coauthor | Wahoub M Hout, MD, FACC, Cath Lab Co-Director, Clinical Assistant Professor of NEOUCOM, Department of Medicine, St Elizabeth Hospital | Nothing to disclose | Details | | Medical Editor | Russell F Kelly, MD, Program Director, Assistant Professor, Department of Internal Medicine, Division of Cardiology, Cook County Hospital, Rush Medical College | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Ronald J Oudiz, MD, Director of Pulmonary Hypertension, Associate Professor, Department of Medicine, Division of Cardiology, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA | Actelion Encysive Gilead Pfizer United Therapeutics | Details | | CME Editor | Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital | Nothing to disclose | Details | | Chief Editor | Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Wahoub M Hout, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Russell F Kelly, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Amer Suleman, CME Editor |
The contributor discloses no conflict of interest. |
|